Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.77 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25842368 | 0.94 | NFE2L2 (0.68) | NFE2L2LY96MAOBALDH1A1POLB | |
| SCHEMBL17899561 | 0.87 | ACHE (0.65) | NFE2L2LY96ALDH1A1MAPTKMT2A | |
| SCHEMBL31518795 | 0.87 | ACHE (0.65) | NFE2L2LY96ALDH1A1MAPTKMT2A | |
| SCHEMBL10033987 | 0.85 | NFE2L2 (0.57) | NFE2L2MAOBALDH1A1POLBMAPT | |
| SCHEMBL17899554 | 0.85 | MAOB (0.57) | NFE2L2MAOBALDH1A1POLBMAPT | |
| SCHEMBL17899539 | 0.85 | NFE2L2 (0.56) | NFE2L2MAOBALDH1A1POLBMAPT | |
| SCHEMBL17899573 | 0.82 | CRHBP (0.76) | NFE2L2MAOBALDH1A1POLBMAPT | |
| SCHEMBL17899518 | 0.82 | NFE2L2 (0.58) | NFE2L2LY96MAPTRAB9AACHE | |
| SCHEMBL17899531 | 0.81 | MAOB (0.70) | NFE2L2LY96MAOBALDH1A1POLB | |
| SCHEMBL17899530 | 0.80 | KMT2A (0.61) | NFE2L2MAOBALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357200-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-09 | — | — | US | disclosed |
| US-11708350-B2 | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents | BAYLOR COLLEGE OF MEDICINE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-16 | — | — | US | disclosed |
| US-11312676-B2 | Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer | BAYLOR COLLEGE OF MEDICINE (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210115017-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | BAYLOR COLLEGE OF MEDICINE (US) | 2021-04-22 | — | — | US | disclosed |
| US-10875841-B2 | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents | BAYLOR COLLEGE OF MEDICINE (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200071300-A1 | Small Molecule Stimulators of Steroid Receptor Coactivator-3 and Methods of Their Use as Cardioprotective and/or Vascular Regenerative Agents | BAYLOR COLLEGE OF MEDICINE (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2017062751-A1 | COMPOUNDS AND METHODS FOR PROMOTING STRESS RESISTANCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016109470-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR PROTEINS AND THEIR USE IN THE TREATMENT OF CANCER | BAYLOR COLLEGE OF MEDICINE (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071300-A1 | Small Molecule Stimulators of Steroid Receptor Coactivator-3 and Methods of Their Use as Cardioprotective and/or Vascular Regenerative Agents | NCOA3, FABP3, NCOA1 | NFE2L2 1274/4885LY96 1393/4885MAOB 4210/4885 |
| US-11312676-B2 | Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer | NCOA2, NCOA1, NCOA3 | NFE2L2 1518/4885LY96 1243/4885MAOB 4723/4885 |
| US-20210115017-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | NCOA3, FABP3, NCOA1 | NFE2L2 1274/4885LY96 1393/4885MAOB 4210/4885 |
| US-11708350-B2 | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents | NCOA3, FABP3, NCOA1 | NFE2L2 1274/4885LY96 1393/4885MAOB 4210/4885 |
| US-10875841-B2 | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents | NCOA3, FABP3, NCOA1 | NFE2L2 1274/4885LY96 1393/4885MAOB 4210/4885 |
| US-11413278-B2 | Compounds and methods for promoting stress resistance | HSPA9, ATF4, GPX4 | NFE2L2 29/4885LY96 3772/4885MAOB 2069/4885 |
| US-20230357200-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | NCOA3, FABP3, NCOA1 | NFE2L2 1274/4885LY96 1393/4885MAOB 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.